Ipamorelin: research overview

The short version

Ipamorelin is a synthetic pentapeptide — five amino acids — that activates the ghrelin receptor (formally, GHS-R1a) on cells in the pituitary gland, triggering a pulse of growth hormone (GH) release. What makes it pharmacologically interesting is what it doesn't do: unlike earlier growth-hormone-releasing peptides, ipamorelin does not meaningfully raise cortisol, ACTH, or prolactin even at doses far above its GH-release threshold ^[16].

Despite widespread use in wellness contexts, ipamorelin has never been approved as a drug anywhere in the world. Its only published Phase 2 randomized controlled trial — in patients recovering from bowel surgery — did not meet its primary endpoint ^[15]. In 2024, the FDA removed ipamorelin acetate from the list of substances eligible for pharmacy compounding. It is prohibited in sport by WADA under category S2 (growth hormone secretagogues).

Human data are limited to one small Phase 1 PK/PD study ^[16] and the failed Phase 2 trial ^[15]. The large body of claimed benefits in wellness promotion rests almost entirely on mechanism and short rodent studies.

What it is

Ipamorelin's sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. The use of alpha-aminoisobutyric acid at position 1 and D-amino acids at positions 3 and 4 confers protease resistance, explaining its relative stability compared to natural ghrelin. It is derived from an earlier compound (GHRP-1) by removing a central dipeptide — a structural simplification that retained GH-secretagogue activity while eliminating much of the off-target hormonal activity.

As a GHS-R1a agonist, it sits in the same receptor-target class as ghrelin itself, anamorelin, and GHRP-6 — but with a selectivity profile that distinguishes it from these peers. It is a research chemical, not a licensed pharmaceutical.

How it works

Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs — the cells responsible for growth hormone secretion. This binding triggers a discrete GH pulse: in healthy male volunteers given IV infusions, the GH peak appeared approximately 40 minutes after dosing ^[16].

Key pharmacological features:

• Selective GH release without cortisol/ACTH/prolactin elevation: Even at doses more than 200-fold above its GH ED50 in preclinical models, ipamorelin does not meaningfully raise stress hormones or prolactin ^[16]. This selectivity is its defining feature.
• Complementary to GHRH: Ipamorelin releases GH via a mechanism distinct from and additive with growth-hormone-releasing hormone (GHRH), which is why it is often studied alongside GHRH analogs in combination protocols — though no controlled human trial of such combinations exists.
• GHS-R1a also expressed outside the pituitary: The ghrelin receptor is present in enteric neurons (affecting gastric motility), hypothalamic appetite circuits (orexigenic effect), and pancreatic islet cells (preclinical insulin-release data). These off-pituitary actions mean ipamorelin is not purely a GH-release tool, even if that is its primary effect.

Terminal half-life in the human PK study was approximately 2 hours, with linear, dose-proportional pharmacokinetics ^[16].

What the research shows

Human PK/PD study (1999): Eight healthy male volunteers per dose level received five 15-minute IV infusions of ipamorelin at escalating doses. Terminal half-life was approximately 2 hours; kinetics were linear and dose-proportional; GH peaked ~40 minutes after dosing as a single discrete pulse. This is one of the only human pharmacokinetic datasets for ipamorelin ^[16].

Bone growth (1999, rats): Subcutaneous ipamorelin dose-dependently increased longitudinal bone growth rate in adult female rats (from 42 to up to 52 μm/day) without measurable change in systemic IGF-1, bone turnover markers, or total IGF-binding proteins — suggesting a partly local or GH-pulse-driven skeletal effect rather than a purely IGF-1-mediated one ^[17].

Phase 2 RCT — postoperative ileus (2014): In 114 adults recovering from bowel resection surgery, IV ipamorelin twice daily for up to 7 days did not significantly reduce the time to first tolerated meal (25.3 hours with ipamorelin vs. 32.6 hours with placebo, p=0.15). The primary endpoint was missed. No ipamorelin-specific safety signal was identified in this short perioperative window ^[15]. This is the defining human efficacy anchor for ipamorelin — and it is a null result.

Class-level cardiovascular signal (2015): A 28-day study of GSK894281, a structurally distinct GHS-R1a agonist in the same receptor class, found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology and elevated serum cardiac markers at the highest doses. Ipamorelin itself was not the tested compound, but the class-level signal is relevant context for chronic GHS-R1a agonism ^[14].

Ferret weight-loss model (2024): Intraperitoneal ipamorelin inhibited cisplatin-induced body-weight loss by approximately 24% versus control in ferrets — but had no anti-emetic effect (unlike a centrally-acting comparator tested in the same study). This is the most recent published in-vivo ipamorelin study ^[13].

Reported effects, cautions & safety

What research-use communities report (anecdotal, not clinical evidence — unverified self-reports with no confirmed doses or clinical oversight)

The most consistently reported benefit is deeper, more restorative sleep — described as appearing within one to two weeks and frequently cited as the principal reason people use ipamorelin at bedtime. Vivid or intense dreams in the first weeks are commonly reported alongside this. Faster recovery between training sessions and reduced muscle soreness are frequently mentioned. Some users describe gradual, subtle improvements in body composition over weeks to months, though these reports are confounded by diet and training variables.

Adverse reports include: facial flushing and a head-rush sensation approximately 5–15 minutes after injection (widely noted and often interpreted as a sign of activity); tingling or numbness in extremities in the early weeks; mild water retention and puffiness; and increased appetite in the hours after dosing (mechanistically consistent with the ghrelin receptor's orexigenic role). A subset of users report that perceived benefits — especially sleep improvements — seem to diminish after three to four months of uninterrupted use.

Safety cautions from the literature:

No approved indication: Ipamorelin has never been approved as a drug, and its only clinical trial missed its efficacy endpoint ^[15]. Widespread wellness promotion runs well ahead of the evidence.

Cancer and IGF-1: GH stimulates hepatic IGF-1 production, and IGF-1 is a well-characterized mitogen. The theoretical concern — that chronically raising GH-pulse amplitude could accelerate proliferative activity in pre-existing or occult tumors — is mechanism-based, not derived from observed events in any ipamorelin study.

Class-level cardiovascular signal: A 28-day study of a related GHS-R1a agonist found myocardial degeneration in rats ^[14]. No equivalent long-duration cardiovascular safety study of ipamorelin exists in any species. This is a class-level caution, particularly relevant for people with underlying cardiac conditions.

WADA prohibition: Ipamorelin is prohibited in sport at all times under the WADA Prohibited List category S2 (growth hormone secretagogues).

Unverified supply: Most available ipamorelin is research-grade material from unregulated suppliers with no pharmaceutical quality assurance.

Where it fits

Among the five compounds here, ipamorelin sits in an interesting middle position: it has two published human studies (small but real), a clean selectivity profile that makes it pharmacologically interesting, and a community of users who report subjective benefits — but also a null Phase 2 efficacy result, WADA prohibition, no approved indication, and a class-level cardiovascular signal that warrants attention for chronic use.

Important distinctions: ipamorelin is not the CJC-1295/ipamorelin blend frequently marketed together — that combination is supported by separate single-agent pharmacology, not by any controlled trial of the combination. It acts on a GH-secretagogue receptor, not on the GH-releasing-hormone receptor; these are complementary pathways but mechanistically distinct. And despite common marketing claims, no controlled human evidence supports its use for anti-aging, fat loss, or muscle gain.